Evidence map›Paper›PMID 41000374›Full record

ArticleMedComm2025

Hypomethylation-Enhanced F-Box Protein 32 Promotes Hepatocellular Carcinogenesis via Ubiquitin-Mediated PHLPP2 Degradation.

Shu Chen, Kai Yu, Zhengming Deng, Xiaopei Hao, Ping Shi, Zhengzheng Wang, Jiali Xu, Jingjing Dai

Abstract read
In one paragraph

Article in MedComm, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Shu ChenDepartment of Hepatobiliary Pancreatic Spleen Surgery The Affiliated Hospital of Jiangsu University Zhenjiang China.
Kai YuHepatobiliary Center, The First Affiliated Hospital With Nanjing Medical University; Key Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences; NHC Key Laboratory of Hepatobiliary Cancers Nanjing Jiangsu Province China.
Zhengming DengDepartment of General Surgery, Jiangsu Province Hospital of Chinese Medicine Affiliated Hospital of Nanjing University of Chinese Medicine Nanjing China.
Xiaopei HaoDepartment of Hepatobiliopancreatic Surgery The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital Zhengzhou China.
Ping ShiDepartment of Infectious Diseases The First Affiliated Hospital With Nanjing Medical University Nanjing Jiangsu Province China.
Zhengzheng WangDepartment of Hepatobiliopancreatic Surgery The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital Zhengzhou China.
Jiali XuDepartment of Anesthesiology, Jinling Hospital, Affiliated Hospital of Medical School Nanjing University Nanjing Jiangsu Province China.
Jingjing DaiDepartment of Infectious Diseases The First Affiliated Hospital With Nanjing Medical University Nanjing Jiangsu Province China.ORCID https://orcid.org/0009-0000-0276-7027

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

F-Box Protein 32 (FBXO32), a F-box protein family member, exhibits oncogenic and tumor-suppressive roles in various carcinomas. However, its function and underlying molecular mechanisms in hepatocellular carcinoma (HCC) are still unknown. We observed that FBXO32 was overexpressed in HCC tissues than normal tissues, which is pertaining to poor prognosis in HCC patients. Functional tests demonstrated that FBXO32 enhanced HCC cell proliferation, invasion, and metastasis, which was confirmed in vivo using mouse models. Proteomics-based approaches and computational analyses reported a positive correlation between FBXO32 and PI3K-AKT pathway, identifying pleckstrin homology domain leucine-rich repeat protein phosphatase 2 (PHLPP2) as an interacting protein. Mechanistically, DNA promoter hypomethylation elevated FBXO32 expression in HCC cells, promoting K48-linked PHLPP2 polyubiquitination at the K592 and K942 sites through direct interactions. Notably, targeting FBXO32 significantly inhibited tumor growth in both an orthotopic HCC model and an organoid model derived from HCC patients. To sum up, this work emphasizes the part of FBXO32 in propelling HCC progression via facilitating PI3K-AKT pathway activation via PHLPP2 degradation.

Indexed as

biomarkerDNA methylationE3 ubiquitin ligasePI3K–AKT pathway

Identifiers

PMID41000374
PMCPMC12457717

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.